Correlation Between Spero Therapeutics and Athira Pharma

Can any of the company-specific risk be diversified away by investing in both Spero Therapeutics and Athira Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spero Therapeutics and Athira Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Spero Therapeutics and Athira Pharma, you can compare the effects of market volatilities on Spero Therapeutics and Athira Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spero Therapeutics with a short position of Athira Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spero Therapeutics and Athira Pharma.

Diversification Opportunities for Spero Therapeutics and Athira Pharma

0.74

Correlation Coefficient

Spero Therapeutics  Athira Pharma

Poor diversification

The 3 months correlation between Spero and Athira is 0.74. Overlapping area represents the amount of risk that can be diversified away by holding Spero Therapeutics and Athira Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Athira Pharma and Spero Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spero Therapeutics are associated (or correlated) with Athira Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Athira Pharma has no effect on the direction of Spero Therapeutics i.e., Spero Therapeutics and Athira Pharma go up and down completely randomly.

Pair Corralation between Spero Therapeutics and Athira Pharma

Given the investment horizon of 90 days Spero Therapeutics is expected to generate 0.93 times more return on investment than Athira Pharma. However, Spero Therapeutics is 1.08 times less risky than Athira Pharma. It trades about -0.09 of its potential returns per unit of risk. Athira Pharma is currently generating about -0.19 per unit of risk. If you would invest  102.00  in Spero Therapeutics on December 28, 2024 and sell it today you would lose (25.35) from holding Spero Therapeutics or give up 24.85% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Spero Therapeutics  vs.  Athira Pharma

Spero Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Spero Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Athira Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Athira Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Spero Therapeutics and Athira Pharma

The main advantage of trading using opposite Spero Therapeutics and Athira Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spero Therapeutics position performs unexpectedly, Athira Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Athira Pharma will offset losses from the drop in Athira Pharma's long position.

The idea behind Spero Therapeutics and Athira Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.